KIT and neuroblastoma: Most approved KIT inhibitors have multiple other targets, so we analyzed the correlation between NB cells sensitivity to FDA-approved kinase inhibitors, which have KIT among their targets, and the dependency of NB cells on these targets according to DepMap RNAi and CRISPR screens [24,25].